ArticleMedical oncology (Northwood, London, England)2012
Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Trial
- Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics Approach.Biomolecules · 2024Article
- Article
- Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine.Diagnostics (Basel, Switzerland) · 2022Article
- Characterization of Proteins Regulated by Androgen and Protein Kinase a Signaling in VCaP Prostate Cancer Cells.Biomedicines · 2021Article
- Integrative analysis of genetic and epigenetic profiling of lung squamous cell carcinoma (LSCC) patients to identify smoking level relevant biomarkers.BioData mining · 2019Article
- Promise and Implementation of Proteomic Prostate Cancer Biomarkers.Diagnostics (Basel, Switzerland) · 2018Review
- Genome-Wide Identification and Characterization of Long Non-Coding RNA in Wheat Roots in Response to CaFrontiers in plant science · 2018Article
- Inosine monophosphate dehydrogenase 2 as a marker of aggressive and advanced prostate cancer.Central European journal of urology · 2018Article
- c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.EBioMedicine · 2017Article
- HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.Oncotarget · 2017Article
- Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.Oncotarget · 2017Review
- Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.Frontiers in oncology · 2017Review
- The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2016Review
- Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer.International journal of molecular medicine · 2016Article
- Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data.OncoTargets and therapy · 2016Article
- Transcriptomic and Proteomic Investigation of HSP90A as a Potential Biomarker for HCC.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.Oncotarget · 2015Article
- Dietary L-arginine supplementation affects the skeletal longissimus muscle proteome in finishing pigs.PloS one · 2015Article
- Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to identify novel serological tumor markers for human prostate cancer (PCa). We compared the gene expression profile of PCa tissues to adjacent benign tissues of prostate using gene expression microarray. 1207 genes that were consistently different from adjacent benign tissues of prostate (paired t test, P<0.05) were selected as differentially expressed genes (DEGs). Among them, 652 DEGs were upregulated in PCa, whereas 555 DEGs were downregulated in PCa. In addition, two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) coupled with MS was performed to screen for candidate markers in the proteome of PCa and adjacent benign tissues of prostate. A total of 89 spots were significantly up-regulated (ratio≥2, P<0.01) in PCa samples, whereas 66 spots were down-regulated (ratio≤-2, P<0.01). Sixty gene products were identified among these spots. Moreover, 14 potential candidate markers, which were identified as differentially expressed molecules by both gene expression microarray and 2D-DIGE, were chosen for validation and analysis by ELISA. The serum levels of three proteins correlated well with the 2D-DIGE results. Furthermore, the increased serum level of Inosine monophosphate dehydrogenase II (IMPDH2) was significantly associated with the clinicopathological features of the patients with PCa, suggesting its potential as a serological tumor marker. These results demonstrated that integrative transcriptome and proteome analysis could be a powerful tool for marker discovery in PCa. We suggest IMPDH2 as a novel serological tumor marker for detection of early PCa and evaluation of tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.